Episode 2 - Immunotherapy in CRPC

During this segment, David Crawford, MD, discusses immunotherapy’s role in castration-resistant prostate cancer (CRPC), and explains how the US Food and Drug Administration’s approval of sipuleucel-T has led to a paradigm shift in the way that CRPC is treated.

Dr Crawford explains the unique capabilities of immunotherapy for advanced disease when compared to conventional treatment options such as cytotoxic chemotherapy.

Additionally, David Quinn, MD, discusses hormonal therapy agents, the key clinical trials that have tested these treatment options, and explains how the trials have demonstrated improved outcomes in CRPC.